JP2024516199A5 - - Google Patents
Info
- Publication number
- JP2024516199A5 JP2024516199A5 JP2023565369A JP2023565369A JP2024516199A5 JP 2024516199 A5 JP2024516199 A5 JP 2024516199A5 JP 2023565369 A JP2023565369 A JP 2023565369A JP 2023565369 A JP2023565369 A JP 2023565369A JP 2024516199 A5 JP2024516199 A5 JP 2024516199A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- reacting
- hcl
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163180043P | 2021-04-26 | 2021-04-26 | |
| US63/180,043 | 2021-04-26 | ||
| US202163286764P | 2021-12-07 | 2021-12-07 | |
| US63/286,764 | 2021-12-07 | ||
| PCT/US2022/026208 WO2022232060A1 (en) | 2021-04-26 | 2022-04-25 | Processes for the synthesis of valbenazine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516199A JP2024516199A (ja) | 2024-04-12 |
| JP2024516199A5 true JP2024516199A5 (enExample) | 2025-05-08 |
Family
ID=81654703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565369A Pending JP2024516199A (ja) | 2021-04-26 | 2022-04-25 | バルベナジンの合成方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240239791A1 (enExample) |
| EP (1) | EP4330255A1 (enExample) |
| JP (1) | JP2024516199A (enExample) |
| CA (1) | CA3215792A1 (enExample) |
| IL (1) | IL307826A (enExample) |
| WO (1) | WO2022232060A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| IL284874B2 (en) | 2015-10-30 | 2023-10-01 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| RS66714B1 (sr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences Inc | Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim |
| IL291221B2 (en) | 2019-09-13 | 2026-05-01 | Neurocrine Biosciences Inc | Processes for the synthesis of valbenazine |
-
2022
- 2022-04-25 WO PCT/US2022/026208 patent/WO2022232060A1/en not_active Ceased
- 2022-04-25 IL IL307826A patent/IL307826A/en unknown
- 2022-04-25 JP JP2023565369A patent/JP2024516199A/ja active Pending
- 2022-04-25 US US18/288,311 patent/US20240239791A1/en active Pending
- 2022-04-25 CA CA3215792A patent/CA3215792A1/en active Pending
- 2022-04-25 EP EP22723872.2A patent/EP4330255A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007330478B2 (en) | Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid | |
| JP2008509953A5 (enExample) | ||
| US8530668B2 (en) | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | |
| JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
| JP2022511029A5 (enExample) | ||
| CA3119807A1 (en) | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| JP2021523208A5 (enExample) | ||
| JP6215399B2 (ja) | ナルトレキソンの製造方法 | |
| JP2025539576A (ja) | イミダゾリノン化合物の医薬製剤、その調製方法及びその使用 | |
| WO2002020539A1 (en) | Adenosine derivatives and use thereof | |
| ES2331487T3 (es) | Forma cristalina estable de bifeprunox mesilato, formas de dosificacion del mismo y metodos de utilizacion. | |
| HU203766B (en) | Process for producing estramustine-esters and pharmaceutical compositions containing them as active components | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| ES2651962T3 (es) | Derivados de bis-MMF | |
| US20110269838A1 (en) | Novel processes and pure polymorphs | |
| EP1682124B1 (fr) | Compositions pharmaceutiques a base de sel d'idazoxan ou d´un de ses polymorphes | |
| JPS58208275A (ja) | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 | |
| WO1993023360A1 (en) | Novel quaternary ammonium salts and use thereof as medicine | |
| US20240239791A1 (en) | Processes for the synthesis of valbenazine | |
| CN1617857A (zh) | 2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途 | |
| US8754129B2 (en) | Crystalline vorinostat form VI | |
| CH641773A5 (fr) | Derives de 6-methoxy-2-acetylnaphtalene oxime, procede de leur preparation et medicament comportant de ces derives. | |
| CN112979572B (zh) | 一种帕瑞昔布衍生物及其制备方法和应用 | |
| JP6421873B2 (ja) | テノホビルジソプロキシルの新規塩 | |
| CN113501846B (zh) | 艾美酚胺替诺福韦半富马酸复合物、晶型及其制备方法和应用 |